Jeffrey Tate - 20 Oct 2023 Form 4 Insider Report for Cyclo Therapeutics, Inc. (CYTH)

Reporting relationship: Chief Operating Officer, Director
Issuer ticker: CYTH
Reported as of: 20 Oct 2023
Net transaction value: +$17,515
SEC form: 4
Accepted by SEC: 23 Oct 2023, 06:06:05 UTC
Prior SEC filing: 24 Apr 2023
Next SEC filing: 05 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Tate

Key filing fact

Jeffrey Tate filed Form 4 for Cyclo Therapeutics, Inc. (CYTH) on 23 Oct 2023.

Key facts

This page summarizes Jeffrey Tate's Form 4 filing for Cyclo Therapeutics, Inc. (CYTH).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Oct 2023, 06:06.

Change

Previous filing in this sequence was filed on 24 Apr 2023.
Current net transaction value: +$17,515.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYTH transaction

Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value: $21,258
Shares: +29,941
Change %: +48%
Price: $0.7100
Shares after: 92,042
Date: 20 Oct 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYTH transaction Derivative

Warrant to Purchase Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value: $3,743
Shares: -29,941
Change %: -100%
Price: $0.1250
Shares after: 0
Date: 20 Oct 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,941
Exercise price: $0.7100

CYTH transaction Derivative

Warrant to Purchase Common Stock

Purchase

Transaction value
Shares: +32,935
Change %
Price
Shares after: 32,935
Date: 20 Oct 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,935
Exercise price: $0.9500
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 29,941 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised his Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants.